Retroperitoneal extension of massive ulcerated testicular seminoma through the inguinal canal: A case report
Introduction: Testicular cancers represent about 5% of all urological malignancies and 1-1.5% of all male neoplasms. Most of the testicular cancers are localized (68%) at diagnosis. Bulky masses in the scrotum are rare. We present a rare case of bulky testicular cancer with retroperitoneal spread through the inguinal canal.
Case report: A 44-year-old man came to the emergency department referring weakness and the presence of a scrotal mass. At physical examination, a voluminous mass was found, with necrotic phenomena within the scrotum. Abdomen was tense and sore. Abdominal CT scan revealed a bulky testicular mass spreading to the retroperitoneal space through the inguinal canal with node enlargement. Patient underwent orchiectomy with excision of infiltrated scrotum skin. Histologic diagnosis confirmed a typical form seminoma. The patient was then treated with a cisplatin-based chemotherapy, with a partial response. The patient recently relapsed and he is being treated with a new line of chemotherapy and subsequent surgery with or without radiotherapy.
Conclusions: We described a rare presentation of testicular cancer. This case highlights the importance of a multidisciplinary approach to rare testis tumour presentation and early diagnosis for testicular cancers.
Chia VM, Quraishi SM, Devesa SS, et al. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomark Prev. 2010; 19:1151-9. DOI: https://doi.org/10.1158/1055-9965.EPI-10-0031
Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol. 2003; 170:5-11. DOI: https://doi.org/10.1097/01.ju.0000053866.68623.da
Shanmugalingam T, Soultati A, Chowdhury S, et al. Global incidence and outcome of testicular cancer. Clin Epidemiol. 2013;5:417-27.
Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: Renal, penile, and testicular tumours. Eur Urol. 2016; 70:93-105. DOI: https://doi.org/10.1016/j.eururo.2016.02.029
Palumbo C, Mistretta FA, Mazzone E, et al. Contemporary incidence and mortality rates in patients with testicular germ cell tumors. Clin Genitourin Cancer. 2019; 17:e1026-35. DOI: https://doi.org/10.1016/j.clgc.2019.06.003
Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol. 1998; 16:702-6. DOI: https://doi.org/10.1200/JCO.19188.8.131.522
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 1990. 2009; 45:228-47.
Mihor A, Tomsic S, Zagar T, et al. Socioeconomic Inequalities in Cancer Incidence in Europe: A Comprehensive Review of Populationbased Epidemiological Studies. Radiol Oncol. 2020; 54:1-13. DOI: https://doi.org/10.2478/raon-2020-0008
Marchioni M, Martel T, Bandini M, et al. Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1-2 N0 M0 renal cell carcinoma. World J Urol. 2017;35:1899-905. DOI: https://doi.org/10.1007/s00345-017-2082-9
Macleod LC, Cannon SS, Ko O, Schade GR, et al. Disparities in Access and Regionalization of Care in Testicular Cancer. Clin Genitourin Cancer. 2018; 16:e785-93. DOI: https://doi.org/10.1016/j.clgc.2018.02.014
Honecker F, Aparicio J, Berney D, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018; 29:1658-86. DOI: https://doi.org/10.1093/annonc/mdy217
Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448-52. DOI: https://doi.org/10.1200/JCO.2002.01.038
Aparicio J, Germà JR, García del Muro X, et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol. 2005; 23:8717-23. DOI: https://doi.org/10.1200/JCO.2005.01.9810
Park S, Lee S, Lee J, et al. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed orcisplatin-refractory germ cell tumors. Onkologie. 2011; 34:416-20. DOI: https://doi.org/10.1159/000331129
Oldenburg J, Fosså SD, Nuver J, et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2013;24 Suppl 6:vi125-132. DOI: https://doi.org/10.1093/annonc/mdt304
- Abstract views: 252
- PDF: 128
Copyright (c) 2021 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.